Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making  Roza Ismailovna Yagudina, PhD, Andrey Urievich.

Slides:



Advertisements
Similar presentations
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Advertisements

Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results  Becky Pennington, MSc,
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 15, Issue 2, Pages (March 2012)
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Volume 14, Issue 8, Pages (December 2011)
Value in Health Regional Issues
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine.
Value in Health Regional Issues
Value in Health Regional Issues
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
Value in Health Regional Issues
The Development of the Romanian Scorecard HTA System
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan  Kaoru Yamabe, MSc, Puneet K. Singhal,
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Value in Health Regional Issues
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Value in Health Regional Issues
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs)
The Process of Privatization of Health Care Provision in Poland
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
Drug Policy in Bulgaria
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Value in Health Regional Issues
Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm 
Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam  Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
Value in Health Regional Issues
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel 
Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia 
Advancing the Visibility, Impact, and Quality Metrics of Value in Health Regional Issues  Dan Greenberg, PhD, Imre Boncz, MD, MSc, PhD, Habil, Ahmed Awaisu,
Omneya Mohamed, PhD, David H. Kreling, PhD 
Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M
Value in Health Regional Issues
The Economic Impact of Cigarette Smoking on the Poor in Jordan
A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations  Panagiotis Petrou, MBA, PhD, PhDc, Michalis.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective  Bruno Salgado Riveros,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Cost-Effectiveness Analysis Expands its Reach Worldwide
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System  Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Guidance Document: Global Pharmacoeconomic Model Adaption Strategies
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia  Vlado Jukic, MD, PhD, Miro Jakovljevic, MD, PhD, Igor Filipcic,
Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries  Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.
Victoria I. Ignatyeva, MPH, Johan L
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Drug Policy in Hungary Value in Health Regional Issues
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Evaluation of Quality of Pharmacoeconomic Studies in Asia-Pacific Region and Identification of Influencing Variables  Prabhakar Pandey, MPharm, Rishabh.
Lars Oddershede, MMS, Jan J. Andreasen, MD, PhD, Barbara C
Presentation transcript:

Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making  Roza Ismailovna Yagudina, PhD, Andrey Urievich Kulikov, PhD, Vjacheslav Gennadievich Serpik, PhD, Dzhumber Tengizovich Ugrekhelidze, MSc  Value in Health Regional Issues  Volume 13, Pages 61-66 (September 2017) DOI: 10.1016/j.vhri.2017.07.006 Copyright © 2017 Terms and Conditions

Fig. 1 Graphical representation of cost-effectiveness analysis WTP - willingness-to-pay, ICER - incremental cost-effectiveness ratio, CER - cost-effectiveness ratio, GDP - gross domestic product, QALY - quality-adjusted life year, LYG - life years gained. Value in Health Regional Issues 2017 13, 61-66DOI: (10.1016/j.vhri.2017.07.006) Copyright © 2017 Terms and Conditions

Fig. 2 Graphical representation of budget impact analysis. Value in Health Regional Issues 2017 13, 61-66DOI: (10.1016/j.vhri.2017.07.006) Copyright © 2017 Terms and Conditions

Fig. 3 «3D» pharmacoeconomic model of health technology approval area used in their inclusion in state funding programs based on pharmacoeconomic criteria: cost-effectiveness analysis and budget impact analysis. BIA - budget impact analysis. Value in Health Regional Issues 2017 13, 61-66DOI: (10.1016/j.vhri.2017.07.006) Copyright © 2017 Terms and Conditions

Fig. 4 Basic diagram of three-dimensional (3D) model of decision-making based on pharmacoeconomic cost-effectiveness analysis and budget impact analysis. Value in Health Regional Issues 2017 13, 61-66DOI: (10.1016/j.vhri.2017.07.006) Copyright © 2017 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.